中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:13 更新时间:2024-11-21
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:010-64840910,80117700

千城特选小程序码

7×24h 快讯

李彦宏:百度文库AI功能月活用户超5000万,同比增长超300%

36氪获悉,百度2024年第三季度财报电话会上,百度创始人、董事长兼首席执行官李彦宏披露,今年9月,百度文库AI功能月活用户突破5000万,同比增长超300%。此外,用户的付费意愿不断增强,第三季度文库的订阅收入同比增长23%。在近期举办的百度世界2024上,百度文库与百度网盘联合推出了工具类智能体“自由画布”,亮相首日即吸引超20万人排队预约。

52分钟前

李彦宏:Q3智能云营收快速增长,AI收入占比提升至超11%

36氪获悉,在百度2024年第三季度财报电话会上,百度创始人、董事长兼首席执行官李彦宏公布,三季度,百度智能云营收达49亿元,同比增长11 %,Non-GAAP 经营利润率同比提升。其中,AI相关收入占比持续提升至超11%。据IDC报告,在中国AI公有云市场,百度智能云已连续五年位居第一。

52分钟前

热门中概股美股盘前普跌,拼多多跌超10%

36氪获悉,热门中概股美股盘前普跌,截至发稿,拼多多跌超10%,小鹏汽车、爱奇艺跌超4%,百度、B站跌超2%,蔚来跌超1%。

52分钟前

我国载人登月任务已全面进入初样研制阶段

中国载人航天工程总设计师周建平21日在深圳召开的第六届载人航天学术大会上表示,我国载人月球探测工程载人登月任务已经完成了前期的关键技术攻关和深化论证,目前全面进入了初样研制阶段。“目前,长征十号运载火箭、梦舟载人飞船、揽月月面着陆器、载人月球车等初样产品正在紧张研制过程中。不少初样产品已经研制出来,正在进行相关测试。”周建平说。(新华社)

52分钟前

李彦宏:百度将于2025年初发布新版大模型

36氪获悉,在百度2024年第三季度财报电话会上,百度创始人、董事长兼首席执行官李彦宏透露,百度将于2025年初发布文心大模型的新版本,以巩固在基础模型上的领先优势。李彦宏表示,11月,文心大模型日均调用量达15亿,日均处理Tokens文本超1.7万亿。相较一年前首次披露的5000万次日均调用量,增长30倍。

52分钟前

本页详细列出关于卡尤迪COYOTE的品牌信息,含品牌所属公司介绍,卡尤迪COYOTE所处行业的品牌地位及优势。
咨询